Francesco Galimi - Apr 1, 2022 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Role
SVP & Chief Medical Officer
Signature
/s/ Nick Harvey, Attorney-in-Fact
Stock symbol
ACET
Transactions as of
Apr 1, 2022
Transactions value $
-$171,146
Form type
4
Date filed
4/5/2022, 06:23 PM
Previous filing
Feb 16, 2022
Next filing
Aug 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACET Common Stock Options Exercise $45.5K +7.62K +12.72% $5.97 67.5K Apr 1, 2022 Direct F1
transaction ACET Common Stock Sale -$160K -7.62K -11.28% $21.00* 59.9K Apr 1, 2022 Direct F1
transaction ACET Common Stock Options Exercise $80.1K +6.04K +10.07% $13.27* 66K Apr 4, 2022 Direct F1
transaction ACET Common Stock Sale -$127K -6.04K -9.15% $21.00* 59.9K Apr 4, 2022 Direct F1
transaction ACET Common Stock Options Exercise $1K +168 +0.28% $5.97 60.1K Apr 4, 2022 Direct F1
transaction ACET Common Stock Sale -$3.53K -168 -0.28% $21.00* 59.9K Apr 4, 2022 Direct F1
transaction ACET Common Stock Options Exercise $29.9K +1.78K +2.96% $16.82* 61.7K Apr 4, 2022 Direct F1
transaction ACET Common Stock Sale -$37.3K -1.78K -2.88% $21.00* 59.9K Apr 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACET Employee Stock Option (Right to Buy) Options Exercise -7.62K -6.28% 114K Apr 1, 2022 Common Stock 7.62K $5.97 Direct F1, F2, F3
transaction ACET Employee Stock Option (Right to Buy) Options Exercise $0 -6.04K -7.55% $0.00 74K Apr 4, 2022 Common Stock 6.04K $13.27 Direct F1, F4
transaction ACET Employee Stock Option (Right to Buy) Options Exercise -168 -0.15% 114K Apr 4, 2022 Common Stock 168 $5.97 Direct F1, F2, F3
transaction ACET Employee Stock Option (Right to Buy) Options Exercise $0 -1.78K -6.25% $0.00 26.6K Apr 4, 2022 Common Stock 1.78K $16.82 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021.
F2 A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date.
F3 Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."
F4 A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.
F5 A total of 28,400 shares subject to an employee stock option were granted on February 12, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.